The New World of Life Sciences M&A Valuation: Strategies to Adapt and Thrive

11:00 AM - 12:15 PM, Tuesday, June 4, 2019 ・ 109AB, Level 100
In recent years, there’s been a scarcity of high quality, revenue-generating biopharma assets. This dearth, coupled with larger pharma’s growth requirements, has led to a significant run up in valuations of private and public biotech assets. As a result, organizations have been forced to adopt new and more advanced valuation techniques to appropriately evaluate acquisition targets. Representatives from the industry’s most successful pharma/biotech organizations will share insights and best practices for capturing and analyzing the most relevant aspects in designing a comprehensive valuation for M&A and what challenges remain.
Senior VP, Worldwide Business Development
Pfizer Inc
SVP, Business Development & Strategy, and GM, International Operations
Mallinckrodt Pharmaceuticals
Head of Corporate Development and Business Development Finance
Takeda Pharmceuticals
Vice Chairman of Healthcare Investment Banking
Wells Fargo Securities, LLC